TECX Tectonic Therapeutic, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TECX matters now
Tectonic Therapeutic, Inc. (TECX) is a US stock in Healthcare. The latest InvestLog snapshot shows $34.37 with -2.55% on the session and $648.5M in market capitalization; recent performance reads 1-month +10.00% and YTD +43.91%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-25.2M, and EPS of $-1.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.6%.
The latest indexable market news headline is "Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $75.00; recent insider activity includes Lochner Daniel filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.45
P/S
0.00
EV/EBITDA
-4.15
DCF Value
$13.73
FCF Yield
-11.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.3%
ROA
-33.9%
ROIC
-39.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-25.2M | $-1.34 |
| Q4 2025 | $0.00 | $-19.2M | $-1.03 |
| FY 2025 | $0.00 | $-74.2M | $-4.05 |
| Q3 2025 | $0.00 | $-19.0M | $-1.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$72.00
Target (Median)
$75.00
Target Range
$60.00 - $81.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.22
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.